Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Minimed Group's Days Sales Outstanding for the
three
months ended in Apr. 2026 was 46.33.
Minimed Group's Days Inventory for the
three
months ended in Apr. 2026 was 95.35.
Minimed Group's Days Payable for the
three
months ended in Apr. 2026 was 59.37.
Therefore, Minimed Group's Cash Conversion Cycle (CCC) for the
three
months ended in Apr. 2026 was 82.31.
Minimed Group (STU:B8S) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Minimed Group Cash Conversion Cycle Related Terms
Minimed Group Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Minimed Group's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:B8S vs MMSI, NVST, STVN: Cash Conversion Cycle Comparison
For the Medical Instruments & Supplies subindustry, Minimed Group's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minimed Group Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Minimed Group's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Minimed Group's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Minimed Group's Cash Conversion Cycle for the fiscal year that ended in Apr. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minimed Group (STU:B8S) has a Cash Conversion Cycle of 82.31 as of Apr. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Minimed Group and its competitors.
Is Minimed Group's Cash Conversion Cycle too high?
Minimed Group's current Cash Conversion Cycle is 82.31. The Medical Devices & Instruments industry median Cash Conversion Cycle is 160.44. Minimed Group's value of 82.31 is 48.7% below this industry median. Overall, Minimed Group has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's Cash Conversion Cycle compare to MMSI and NVST?
Minimed Group's Cash Conversion Cycle of 82.31 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 160.44. Minimed Group's value of 82.31 is 48.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 160.44, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minimed Group's current Cash Conversion Cycle of 82.31 is 48.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Minimed Group and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 160.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minimed Group's current Cash Conversion Cycle is 82.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (STU:B8S) has a current Cash Conversion Cycle of 82.31. The current Cash Conversion Cycle is 82.31 and 48.7% below the Medical Devices & Instruments industry median of 160.44. Minimed Group's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Minimed Group (STU:B8S), the current Cash Conversion Cycle is 82.31 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
20GF Score
Get the complete analysis for STU:B8S
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:B8S has been successfully added to your 
